On August 26, 2021 OntadaTM, McKesson’s oncology and insights business, reported a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation OntadaTM, McKesson’s oncology and insights business, reported a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care. Ontada and Merck’s combined experience and expertise can help enable the confidence, acceptance, and ultimately impact of RWE on the quality of patient care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Susan Shiff, PhD, president of Ontada, shared, "Building on McKesson’s long history in community oncology, Ontada is uniquely positioned to advance cancer care by enabling collaboration between life sciences companies and oncology providers. With data insights from greater than two million records available for research and more than 2,000 oncology providers, Ontada helps life sciences companies like Merck leverage real-world data (RWD) and evidence-based insights at the point of care to accelerate innovation and improve cancer therapy."

As part of the agreement, Merck and Ontada can collaborate on RWD studies to explore new scientific evidence, advanced methods development, and assessment of efficiency in cancer care.

"Merck is focused on bringing excellence to RWE generation by advancing methods and applying rigorous methods to gain RWD based insights," said Ravinder Dhawan, PhD, Vice President and Head, Center for Observational and Real-World Evidence (CORE), Merck Research Laboratories. "We look forward to working with Ontada on our shared purpose of improving the lives of patients with cancer."

"The patients we serve depend on strong relationships between oncology insights leaders like Ontada, life science innovators like Merck, and oncology providers," said Dr. Michael Seiden, MD, PhD, president, The US Oncology Network. "RWD studies build on the body of evidence that oncology providers use in their treatment decision making, and innovation depends on all of us working together to achieve continued improvements in patient outcomes."

Ontada combines real-world data and research capabilities, targeted channels to connect life sciences and providers for education and engagement, and a leading suite of technologies for oncology clinicians – including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool – with the reach of The US Oncology Network, supported by McKesson.. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care. Ontada and Merck’s combined experience and expertise can help enable the confidence, acceptance, and ultimately impact of RWE on the quality of patient care.

Susan Shiff, PhD, president of Ontada, shared, "Building on McKesson’s long history in community oncology, Ontada is uniquely positioned to advance cancer care by enabling collaboration between life sciences companies and oncology providers. With data insights from greater than two million records available for research and more than 2,000 oncology providers, Ontada helps life sciences companies like Merck leverage real-world data (RWD) and evidence-based insights at the point of care to accelerate innovation and improve cancer therapy."

As part of the agreement, Merck and Ontada can collaborate on RWD studies to explore new scientific evidence, advanced methods development, and assessment of efficiency in cancer care.

"Merck is focused on bringing excellence to RWE generation by advancing methods and applying rigorous methods to gain RWD based insights," said Ravinder Dhawan, PhD, Vice President and Head, Center for Observational and Real-World Evidence (CORE), Merck Research Laboratories. "We look forward to working with Ontada on our shared purpose of improving the lives of patients with cancer."

"The patients we serve depend on strong relationships between oncology insights leaders like Ontada, life science innovators like Merck, and oncology providers," said Dr. Michael Seiden, MD, PhD, president, The US Oncology Network. "RWD studies build on the body of evidence that oncology providers use in their treatment decision making, and innovation depends on all of us working together to achieve continued improvements in patient outcomes."

Ontada combines real-world data and research capabilities, targeted channels to connect life sciences and providers for education and engagement, and a leading suite of technologies for oncology clinicians – including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool – with the reach of The US Oncology Network, supported by McKesson.